Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2003-

ABSTRACT

The purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard therapy or are not considered by their physician to have a reasonable chance of collecting enough cells for transplant. Detailed Description The purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard therapy or are not considered by their physician to have a reasonable chance of collecting enough cells for transplant. Compassionate use is a way to provide experimental treatment to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Peripheral blood stem cells are obtained by apheresis following a stem cell mobilization regimen. The standard of care regimen for stem cell mobilization includes a growth factor, G-CSF. AMD3100 is given in addition to G-CSF prior to each apheresis session. If enough peripheral blood stem cells for transplant are collected, the patient is treated with high dose chemotherapy in preparation for transplant and is transplanted with cells obtained from the AMD3100 and G-CSF regimen. Patients are followed for safety and transplant outcomes for up to 12 months after transplant. More... »

URL

https://clinicaltrials.gov/show/NCT00291811

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard therapy or are not considered by their physician to have a reasonable chance of collecting enough cells for transplant.\n\nDetailed Description\nThe purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard therapy or are not considered by their physician to have a reasonable chance of collecting enough cells for transplant. Compassionate use is a way to provide experimental treatment to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Peripheral blood stem cells are obtained by apheresis following a stem cell mobilization regimen. The standard of care regimen for stem cell mobilization includes a growth factor, G-CSF. AMD3100 is given in addition to G-CSF prior to each apheresis session. If enough peripheral blood stem cells for transplant are collected, the patient is treated with high dose chemotherapy in preparation for transplant and is transplanted with cells obtained from the AMD3100 and G-CSF regimen. Patients are followed for safety and transplant outcomes for up to 12 months after transplant.", 
    "id": "sg:clinicaltrial.NCT00291811", 
    "keywords": [
      "protocol", 
      "AMD3100", 
      "peripheral blood stem cell", 
      "transplantation", 
      "access", 
      "patient", 
      "autologous stem cell transplant", 
      "cell", 
      "Transplant", 
      "standard therapy", 
      "physician", 
      "reasonable chance", 
      "trial", 
      "experimental treatment", 
      "therapy", 
      "clinical trial", 
      "life-threatening illness", 
      "Blood Component Removal", 
      "stem cell", 
      "regimen", 
      "Hematopoietic Stem Cell Mobilization", 
      "growth factor", 
      "Granulocyte Colony-Stimulating Factor", 
      "session", 
      "high-dose chemotherapy", 
      "preparation", 
      "safety", 
      "transplant outcome"
    ], 
    "name": "Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00291811"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00002.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.417555.7", 
        "type": "Organization"
      }
    ], 
    "startDate": "2003-10-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/bmt.2013.10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043164854", 
          "https://doi.org/10.1038/bmt.2013.10"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00291811"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00291811'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00291811'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00291811'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00291811'


 

This table displays all metadata directly associated to this object as RDF triples.

50 TRIPLES      15 PREDICATES      43 URIs      36 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00291811 schema:about anzsrc-for:3048
2 schema:description The purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard therapy or are not considered by their physician to have a reasonable chance of collecting enough cells for transplant. Detailed Description The purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard therapy or are not considered by their physician to have a reasonable chance of collecting enough cells for transplant. Compassionate use is a way to provide experimental treatment to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Peripheral blood stem cells are obtained by apheresis following a stem cell mobilization regimen. The standard of care regimen for stem cell mobilization includes a growth factor, G-CSF. AMD3100 is given in addition to G-CSF prior to each apheresis session. If enough peripheral blood stem cells for transplant are collected, the patient is treated with high dose chemotherapy in preparation for transplant and is transplanted with cells obtained from the AMD3100 and G-CSF regimen. Patients are followed for safety and transplant outcomes for up to 12 months after transplant.
3 schema:keywords AMD3100
4 Blood Component Removal
5 Granulocyte Colony-Stimulating Factor
6 Hematopoietic Stem Cell Mobilization
7 Transplant
8 access
9 autologous stem cell transplant
10 cell
11 clinical trial
12 experimental treatment
13 growth factor
14 high-dose chemotherapy
15 life-threatening illness
16 patient
17 peripheral blood stem cell
18 physician
19 preparation
20 protocol
21 reasonable chance
22 regimen
23 safety
24 session
25 standard therapy
26 stem cell
27 therapy
28 transplant outcome
29 transplantation
30 trial
31 schema:name Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation
32 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00291811
33 schema:sdDatePublished 2019-03-07T15:22
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher N275a7d189f9545d98d6e6f76fb9d15a6
36 schema:sponsor https://www.grid.ac/institutes/grid.417555.7
37 schema:startDate 2003-10-01T00:00:00Z
38 schema:subjectOf sg:pub.10.1038/bmt.2013.10
39 schema:url https://clinicaltrials.gov/show/NCT00291811
40 sgo:license sg:explorer/license/
41 sgo:sdDataset clinical_trials
42 rdf:type schema:MedicalStudy
43 N275a7d189f9545d98d6e6f76fb9d15a6 schema:name Springer Nature - SN SciGraph project
44 rdf:type schema:Organization
45 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
46 rdf:type schema:DefinedTerm
47 sg:pub.10.1038/bmt.2013.10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043164854
48 https://doi.org/10.1038/bmt.2013.10
49 rdf:type schema:CreativeWork
50 https://www.grid.ac/institutes/grid.417555.7 schema:Organization
 




Preview window. Press ESC to close (or click here)


...